Symbols / ALT
ALT Chart
About
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 571.13M |
| Enterprise Value | 281.57M | Income | -83.92M | Sales | 20.00K |
| Book/sh | 1.94 | Cash/sh | 2.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 59 | IPO | — |
| P/E | — | Forward P/E | -3.66 | PEG | — |
| P/S | 28556.54 | P/B | 2.35 | P/C | — |
| EV/EBITDA | -3.12 | EV/Sales | 14078.53 | Quick Ratio | 16.83 |
| Current Ratio | 17.18 | Debt/Eq | 8.57 | LT Debt/Eq | — |
| EPS (ttm) | -1.07 | EPS next Y | -1.25 | EPS Growth | — |
| Revenue Growth | 0.00% | Earnings | 2026-02-26 | ROA | -30.87% |
| ROE | -52.62% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -4171.80% | Profit Margin | 0.00% | Shs Outstand | 125.23M |
| Shs Float | 103.53M | Short Float | 19.39% | Short Ratio | 3.78 |
| Short Interest | — | 52W High | 7.73 | 52W Low | 2.90 |
| Beta | 0.08 | Avg Volume | 4.94M | Volume | 902.38K |
| Target Price | $17.67 | Recom | None | Prev Close | $4.57 |
| Price | $4.56 | Change | -0.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.67
Mean price target
2. Current target
$4.56
Latest analyst target
3. DCF / Fair value
$-5.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.56
Low
$1.00
High
$28.00
Mean
$17.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-07 | main | Citizens | Market Outperform → Market Outperform | $14 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-08-13 | main | UBS | Buy → Buy | $24 |
| 2025-08-13 | main | B. Riley Securities | Buy → Buy | $18 |
| 2025-07-10 | main | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-06-27 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-02 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $25 |
| 2025-03-14 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $25 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-28 | init | William Blair | — → Market Perform | — |
| 2025-02-05 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-08 | init | Stifel | — → Buy | $18 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-12 | init | UBS | — → Buy | $26 |
| 2024-08-12 | reit | B. Riley Securities | Buy → Buy | $20 |
News
RSS: Latest ALT news- Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Yahoo Finance Mon, 02 Feb 2026 08
- Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters ue, 03 Feb 2026 08
- Blue Owl Move to Curb Redemptions at Private-Credit Fund Hits Alt Manager Stocks - Barron's hu, 19 Feb 2026 21
- $ALT stock is down 12% today. Here's what we see in our data. - Quiver Quantitative Wed, 28 Jan 2026 08
- Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Nasdaq hu, 11 Dec 2025 08
- Trial drug for fatty liver disease improves key markers at 48 weeks - Stock Titan Fri, 19 Dec 2025 08
- Altimmune, Inc. (ALT) Stock Analysis: Exploring A 311% Potential Upside In Biotech - DirectorsTalk Interviews Fri, 10 Oct 2025 07
- ALT Stock Rallies 4% — What Does Retail Think? - Stocktwits hu, 22 Jan 2026 08
- Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Finviz Wed, 18 Feb 2026 01
- Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock² Sat, 31 Jan 2026 08
- ALT Stock News: Altimmune, Inc. Stockholder Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire hu, 14 Aug 2025 07
- Altimmune stock tumbles after MASH drug trial data - Investing.com Fri, 19 Dec 2025 08
- ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - Yahoo Finance ue, 06 Jan 2026 08
- Insider Purchase: Director at $ALT Buys 12,500 Shares - Quiver Quantitative Mon, 22 Dec 2025 08
- Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan ue, 27 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 17050 | — | — | ROBERTS M SCOT | Officer | — | 2026-02-02 00:00:00 | D | nan |
| 1 | 4571 | — | Stock Award(Grant) at price 5.60 per share. | JORDT RAYMOND M | Officer | — | 2026-01-30 00:00:00 | D | 25598.0 |
| 2 | 5567 | — | Stock Award(Grant) at price 5.60 per share. | ROBERTS M SCOT | Officer | — | 2026-01-30 00:00:00 | D | 31175.0 |
| 3 | 6926 | — | Stock Award(Grant) at price 5.60 per share. | GARG VIPIN K. | Director | — | 2026-01-30 00:00:00 | D | 38786.0 |
| 4 | 26775 | — | — | GARG VIPIN K. | Director | — | 2026-01-30 00:00:00 | D | nan |
| 5 | 15850 | — | — | JORDT RAYMOND M | Officer | — | 2026-01-27 00:00:00 | D | nan |
| 6 | 41200 | — | — | GARG VIPIN K. | Director | — | 2026-01-27 00:00:00 | D | nan |
| 7 | 14600 | — | — | JORDT RAYMOND M | Officer | — | 2026-01-23 00:00:00 | D | nan |
| 8 | 14600 | — | — | ROBERTS M SCOT | Officer | — | 2026-01-23 00:00:00 | D | nan |
| 9 | 42050 | — | — | GARG VIPIN K. | Director | — | 2026-01-23 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -94.81M | -75.52M | -84.41M | -85.16M |
| TotalUnusualItems | 0.00 | -12.42M | 0.00 | -11.37M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -12.42M | 0.00 | -11.37M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -95.06M | -88.45M | -84.71M | -97.09M |
| ReconciledDepreciation | 238.00K | 477.00K | 493.00K | 551.00K |
| EBITDA | -94.81M | -87.94M | -84.41M | -96.53M |
| EBIT | -95.05M | -88.41M | -84.90M | -97.08M |
| NetInterestIncome | 8.06M | 7.32M | 2.86M | 198.00K |
| InterestExpense | 9.00K | 35.00K | 8.00K | 5.00K |
| InterestIncome | 8.07M | 7.35M | 2.87M | 203.00K |
| NormalizedIncome | -95.06M | -76.03M | -84.71M | -85.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -95.06M | -88.45M | -84.71M | -97.09M |
| TotalExpenses | 103.19M | 83.94M | 87.67M | 89.95M |
| TotalOperatingIncomeAsReported | -103.17M | -95.93M | -87.74M | -96.91M |
| DilutedAverageShares | 71.00M | 53.25M | 46.93M | 41.28M |
| BasicAverageShares | 71.00M | 53.25M | 46.93M | 41.28M |
| DilutedEPS | -1.34 | -1.66 | -1.81 | -2.35 |
| BasicEPS | -1.34 | -1.66 | -1.81 | -2.35 |
| DilutedNIAvailtoComStockholders | -95.06M | -88.45M | -84.71M | -97.09M |
| NetIncomeCommonStockholders | -95.06M | -88.45M | -84.71M | -97.09M |
| NetIncome | -95.06M | -88.45M | -84.71M | -97.09M |
| NetIncomeIncludingNoncontrollingInterests | -95.06M | -88.45M | -84.71M | -97.09M |
| NetIncomeContinuousOperations | -95.06M | -88.45M | -84.71M | -97.09M |
| TaxProvision | 0.00 | -197.00K | 0.00 | |
| PretaxIncome | -95.06M | -88.45M | -84.91M | -97.09M |
| OtherIncomeExpense | 48.00K | -12.25M | -32.00K | -11.74M |
| OtherNonOperatingIncomeExpenses | 48.00K | 166.00K | -32.00K | -374.00K |
| SpecialIncomeCharges | 0.00 | -12.42M | 0.00 | -11.37M |
| ImpairmentOfCapitalAssets | 0.00 | 12.42M | 0.00 | 11.37M |
| NetNonOperatingInterestIncomeExpense | 8.06M | 7.32M | 2.86M | 198.00K |
| InterestExpenseNonOperating | 9.00K | 35.00K | 8.00K | 5.00K |
| InterestIncomeNonOperating | 8.07M | 7.35M | 2.87M | 203.00K |
| OperatingIncome | -103.17M | -83.51M | -87.74M | -85.54M |
| OperatingExpense | 103.19M | 83.94M | 87.67M | 89.95M |
| ResearchAndDevelopment | 82.23M | 65.80M | 70.54M | 74.54M |
| SellingGeneralAndAdministration | 20.97M | 18.14M | 17.13M | 15.41M |
| GeneralAndAdministrativeExpense | 20.97M | 18.14M | 17.13M | 15.41M |
| OtherGandA | 20.97M | 18.14M | 17.13M | 15.41M |
| TotalRevenue | 20.00K | 426.00K | -68.00K | 4.41M |
| OperatingRevenue | 20.00K | 426.00K | -68.00K | 4.41M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 72.35M | 70.68M | 49.20M | 40.99M |
| ShareIssued | 72.35M | 70.68M | 49.20M | 40.99M |
| TotalDebt | 1.68M | 671.00K | 1.12M | 1.53M |
| TangibleBookValue | 123.51M | 194.10M | 172.87M | 186.72M |
| InvestedCapital | 123.51M | 194.10M | 185.29M | 199.13M |
| WorkingCapital | 126.79M | 197.48M | 175.76M | 185.85M |
| NetTangibleAssets | 123.51M | 194.10M | 172.87M | 186.72M |
| CapitalLeaseObligations | 1.68M | 671.00K | 1.12M | 1.53M |
| CommonStockEquity | 123.51M | 194.10M | 185.29M | 199.13M |
| TotalCapitalization | 123.51M | 194.10M | 185.29M | 199.13M |
| TotalEquityGrossMinorityInterest | 123.51M | 194.10M | 185.29M | 199.13M |
| StockholdersEquity | 123.51M | 194.10M | 185.29M | 199.13M |
| GainsLossesNotAffectingRetainedEarnings | -4.97M | -5.00M | -5.23M | -5.04M |
| OtherEquityAdjustments | -4.97M | -5.00M | -5.23M | -5.04M |
| RetainedEarnings | -561.39M | -466.33M | -377.88M | -293.17M |
| AdditionalPaidInCapital | 689.86M | 665.43M | 568.40M | 497.34M |
| CapitalStock | 7.00K | 7.00K | 5.00K | 4.00K |
| CommonStock | 7.00K | 7.00K | 5.00K | 4.00K |
| TotalLiabilitiesNetMinorityInterest | 15.80M | 16.54M | 21.64M | 19.73M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.33M | 4.40M | 4.58M | 1.45M |
| OtherNonCurrentLiabilities | 3.93M | 4.22M | 3.91M | 330.00K |
| LongTermDebtAndCapitalLeaseObligation | 1.40M | 175.00K | 672.00K | 1.12M |
| LongTermCapitalLeaseObligation | 1.40M | 175.00K | 672.00K | 1.12M |
| CurrentLiabilities | 10.47M | 12.14M | 17.05M | 18.28M |
| OtherCurrentLiabilities | 6.09M | |||
| CurrentDebtAndCapitalLeaseObligation | 279.00K | 496.00K | 452.00K | 411.00K |
| CurrentCapitalLeaseObligation | 279.00K | 496.00K | 452.00K | 411.00K |
| PayablesAndAccruedExpenses | 10.19M | 11.65M | 16.60M | 11.78M |
| CurrentAccruedExpenses | 9.98M | 9.58M | 10.63M | 9.74M |
| InterestPayable | 55.00K | 124.00K | 103.00K | 44.00K |
| Payables | 211.00K | 2.07M | 5.97M | 2.03M |
| TotalTaxPayable | 0.00 | 1.17M | 0.00 | |
| AccountsPayable | 211.00K | 2.07M | 4.80M | 2.03M |
| TotalAssets | 139.31M | 210.64M | 206.93M | 218.87M |
| TotalNonCurrentAssets | 2.05M | 1.01M | 14.12M | 14.74M |
| OtherNonCurrentAssets | 1.64M | 363.00K | 615.00K | 872.00K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 12.42M | 12.42M | |
| OtherIntangibleAssets | 12.42M | 12.42M | ||
| NetPPE | 413.00K | 651.00K | 1.08M | 1.45M |
| AccumulatedDepreciation | -2.21M | -1.98M | -1.50M | -2.05M |
| GrossPPE | 2.63M | 2.63M | 2.58M | 3.50M |
| Leases | 1.75M | 1.75M | 1.75M | 1.79M |
| OtherProperties | 342.00K | 342.00K | 295.00K | 1.04M |
| MachineryFurnitureEquipment | 535.00K | 535.00K | 535.00K | 661.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 137.25M | 209.63M | 192.81M | 204.13M |
| OtherCurrentAssets | 2.20M | 6.92M | 5.36M | 7.95M |
| RestrictedCash | 42.00K | 41.00K | 34.00K | 34.00K |
| PrepaidAssets | 7.95M | |||
| Receivables | 3.12M | 4.85M | 2.54M | 5.84M |
| TaxesReceivable | 2.57M | 3.74M | 2.37M | 5.41M |
| AccountsReceivable | 544.00K | 1.11M | 173.00K | 429.00K |
| CashCashEquivalentsAndShortTermInvestments | 131.89M | 197.81M | 184.88M | 190.30M |
| OtherShortTermInvestments | 94.97M | 62.70M | 73.78M | 0.00 |
| CashAndCashEquivalents | 36.93M | 135.12M | 111.10M | 190.30M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -79.85M | -75.86M | -62.71M | -90.55M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 9.99M | 86.60M | 56.35M | 65.04M |
| CapitalExpenditure | -47.00K | -126.00K | -12.31M | |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 36.97M | 135.16M | 111.13M | 190.34M |
| BeginningCashPosition | 135.16M | 111.13M | 190.34M | 115.95M |
| ChangesInCash | -98.19M | 24.03M | -79.20M | 74.38M |
| FinancingCashFlow | 10.04M | 86.11M | 56.78M | 65.10M |
| CashFlowFromContinuingFinancingActivities | 10.04M | 86.11M | 56.78M | 65.10M |
| NetOtherFinancingCharges | -850.00K | -824.00K | -516.00K | -118.00K |
| ProceedsFromStockOptionExercised | 900.00K | 328.00K | 950.00K | 176.00K |
| NetCommonStockIssuance | 9.99M | 86.60M | 56.35M | 65.04M |
| CommonStockIssuance | 9.99M | 86.60M | 56.35M | 65.04M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -28.39M | 13.73M | -73.40M | 87.52M |
| CashFlowFromContinuingInvestingActivities | -28.39M | 13.73M | -73.40M | 87.52M |
| NetInvestmentPurchaseAndSale | -28.39M | 13.78M | -73.27M | 99.83M |
| SaleOfInvestment | 87.34M | 102.41M | 0.00 | 107.43M |
| PurchaseOfInvestment | -115.73M | -88.63M | -73.27M | -7.59M |
| NetIntangiblesPurchaseAndSale | 0.00 | -195.00K | ||
| PurchaseOfIntangibles | 0.00 | -195.00K | ||
| NetPPEPurchaseAndSale | 0.00 | -47.00K | -126.00K | -12.12M |
| PurchaseOfPPE | 0.00 | -47.00K | -126.00K | -12.12M |
| OperatingCashFlow | -79.85M | -75.81M | -62.59M | -78.24M |
| CashFlowFromContinuingOperatingActivities | -79.85M | -75.81M | -62.59M | -78.24M |
| ChangeInWorkingCapital | 4.48M | -8.27M | 14.11M | -251.00K |
| ChangeInPayablesAndAccruedExpense | -1.97M | -4.62M | 8.16M | -877.00K |
| ChangeInAccruedExpense | -112.00K | -1.88M | 5.39M | -2.30M |
| ChangeInPayable | -1.86M | -2.73M | 2.77M | 1.42M |
| ChangeInAccountPayable | -1.86M | -2.73M | 2.77M | 1.42M |
| ChangeInPrepaidAssets | 4.71M | -1.34M | 2.65M | -5.91M |
| ChangeInReceivables | 1.74M | -2.31M | 3.30M | 6.53M |
| ChangesInAccountReceivables | 567.00K | -938.00K | 256.00K | 4.18M |
| OtherNonCashItems | 86.00K | 700.00K | ||
| StockBasedCompensation | 14.39M | 10.64M | 8.10M | 5.52M |
| AssetImpairmentCharge | 0.00 | 12.42M | 0.00 | 11.95M |
| AmortizationOfSecurities | -3.85M | -2.47M | -698.00K | |
| DepreciationAmortizationDepletion | 238.00K | 477.00K | 493.00K | 551.00K |
| DepreciationAndAmortization | 238.00K | 477.00K | 493.00K | 551.00K |
| Depreciation | 238.00K | 477.00K | 493.00K | |
| OperatingGainsLosses | -48.00K | -154.00K | 34.00K | 384.00K |
| NetForeignCurrencyExchangeGainLoss | -48.00K | -154.00K | 34.00K | 384.00K |
| NetIncomeFromContinuingOperations | -95.06M | -88.45M | -84.71M | -97.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|